Trial Profile
A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone + 60%W805EC) in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs NB 1008 (Primary) ; Influenza virus vaccine; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 05 Apr 2011 ClinicalTrials.gov record identified and integrated.
- 12 Sep 2010 Results were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy